search
Back to results

Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy

Primary Purpose

Lung Cancer, Sarcoidosis, Interstitial Pneumonia

Status
Completed
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
Flexible bronchoscopy in moderate sedation
Oxygen saturation
Blood pressure
Propofol dosage
Recovery time after bronchoscopy
Sponsored by
Daniel Franzen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lung Cancer

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects undergoing a planned, ambulatory flexible bronchoscopy (for transbronchial lung biopsy or endobronchial ultrasound guided procedures) in moderate sedation, aged between 18 and 85 years

Exclusion Criteria:

  • History of solid organ or bone marrow transplantation with the use of an immunosuppressive therapy
  • HIV infection on anti-retroviral therapy
  • Alcohol consumption more than two standard drinks per day
  • Use of illicit drugs (heroin, opiates)
  • Any contraindication to use propofol for sedation (e.g. allergy)
  • Body mass index > 35 kg/m2
  • Mental disorder preventing appropriate judgment concerning study participation
  • Missing written patient's informed consent

Sites / Locations

  • University Hospital Zurich

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Fractionated propofol administration

Propofol-TCI

Arm Description

Flexible bronchoscopy in moderate sedation with fractionated propofol administrations: Patients receive an initial 20 mg of propofol, followed by a carefully titrated dose of10-20 mg propofol based on the clinical response. Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy

Flexible bronchoscopy in moderate sedation with TCI propofol perfusor: Flexible bronchoscopy is started after reaching the initial targeted effect-site concentration (Ce) of 2.5 μg/mL using the Schnider pharmacokinetic model described elsewhere. Thereafter, Ce is adjusted by increments of 0.2 μg/mL depending on the clinical effect, in order to maintain the required level of sedation. Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy The propofol-TCI perfusor is an active infusion system for fluid management. In the study, the Perfusor® Space of B. Braun AG, Melsungen is used exclusively.

Outcomes

Primary Outcome Measures

Mean arterial oxygen saturation
From induction of sedation until recovery (eye opening/answer to verbal stimuli), in average 45 minutes

Secondary Outcome Measures

Number of occasions with recorded an oxygen saturation of < 90%
From induction of sedation until recovery (eye opening/answer to verbal stimuli), in average 45 minutes
Number of an oxygen desaturation of > 4% from baseline
From induction of sedation until recovery (eye opening/answer to verbal stimuli), in average 45 minutes
Number of occasions with a systolic blood pressure < 90 mmHg during bronchoscopy, maximum oxygen requirement,
From induction of sedation until recovery (eye opening/answer to verbal stimuli), in average 45 minutes
Frequency of dose adjustments
From induction of sedation until recovery (eye opening/answer to verbal stimuli), in average 45 minutes
Cumulative propofol dose
At time point when bronchoscope is removed (on average after 45 minutes)
Recovery time after bronchoscopy

Full Information

First Posted
September 15, 2014
Last Updated
April 13, 2016
Sponsor
Daniel Franzen
Collaborators
B. Braun Melsungen AG
search

1. Study Identification

Unique Protocol Identification Number
NCT02246023
Brief Title
Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy
Official Title
Target-controlled Versus Manually-controlled Propofol Sedation in Flexible Bronchoscopy. A Randomized Non-inferiority Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2015
Overall Recruitment Status
Completed
Study Start Date
January 2015 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
February 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Daniel Franzen
Collaborators
B. Braun Melsungen AG

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
After randomization, the subjects undergo flexible bronchoscopy either with fractionated propofol administration or with propofol-TCI. Measurement of blood pressure, heart rate, oxygen saturation, and oxygen requirement are measured continuously during the procedure and thereafter. Cumulative propofol dose, and induction, procedure, and recovery time are noted continuously during and after the procedure.
Detailed Description
In daily clinical praxis, propofol sedation is given manually in repeated doses (fractionated) by a specially-trained nurse in attendance of the bronchoscopist. But, fractionated propofol administration (FPA) may lead to oversedation and enhanced side effects (oxygen desaturation and arterial hypotension), as a stable plasma concentration of propofol is not maintainable. In contrast to FPA, continuous infusions of propofol are commonly used to induce and maintain long-term sedation in intensive care units and general anesthesia. Recently, continuous propofol infusion for sedation in bronchoscopy has been shown comparable to FPA in terms of safety and efficacy. Generally, infusion devices can be manually controlled (MCI) or target-controlled (TCI). In the latter, the physician sets a target blood concentration and the computerized infusion device makes the necessary changes to the infusion rate. The objective of this study is to compare propofol TCI with FPA in flexible bronchoscopy concerning patient safety and sedation quality.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer, Sarcoidosis, Interstitial Pneumonia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
78 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Fractionated propofol administration
Arm Type
Active Comparator
Arm Description
Flexible bronchoscopy in moderate sedation with fractionated propofol administrations: Patients receive an initial 20 mg of propofol, followed by a carefully titrated dose of10-20 mg propofol based on the clinical response. Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy
Arm Title
Propofol-TCI
Arm Type
Experimental
Arm Description
Flexible bronchoscopy in moderate sedation with TCI propofol perfusor: Flexible bronchoscopy is started after reaching the initial targeted effect-site concentration (Ce) of 2.5 μg/mL using the Schnider pharmacokinetic model described elsewhere. Thereafter, Ce is adjusted by increments of 0.2 μg/mL depending on the clinical effect, in order to maintain the required level of sedation. Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy The propofol-TCI perfusor is an active infusion system for fluid management. In the study, the Perfusor® Space of B. Braun AG, Melsungen is used exclusively.
Intervention Type
Device
Intervention Name(s)
Flexible bronchoscopy in moderate sedation
Intervention Description
Flexible bronchoscopy for diagnosis of lung cancer, sarcoidosis or interstitial pneumonia in moderate sedation with propofol;
Intervention Type
Device
Intervention Name(s)
Oxygen saturation
Intervention Description
Continuous measurement of oxygen saturation;
Intervention Type
Device
Intervention Name(s)
Blood pressure
Intervention Description
Measurement of non-invasive blood pressure every 3 minutes
Intervention Type
Device
Intervention Name(s)
Propofol dosage
Intervention Description
Report of dose adjustments und cumulative propofol dosage;
Intervention Type
Device
Intervention Name(s)
Recovery time after bronchoscopy
Intervention Description
Recovery time after bronchoscopy from removal of bronchoscope to eye opening/answer to verbal stimuli (whatever comes first)
Primary Outcome Measure Information:
Title
Mean arterial oxygen saturation
Description
From induction of sedation until recovery (eye opening/answer to verbal stimuli), in average 45 minutes
Time Frame
During bronchoscopy
Secondary Outcome Measure Information:
Title
Number of occasions with recorded an oxygen saturation of < 90%
Description
From induction of sedation until recovery (eye opening/answer to verbal stimuli), in average 45 minutes
Time Frame
During bronchoscopy
Title
Number of an oxygen desaturation of > 4% from baseline
Description
From induction of sedation until recovery (eye opening/answer to verbal stimuli), in average 45 minutes
Time Frame
During bronchoscopy
Title
Number of occasions with a systolic blood pressure < 90 mmHg during bronchoscopy, maximum oxygen requirement,
Description
From induction of sedation until recovery (eye opening/answer to verbal stimuli), in average 45 minutes
Time Frame
During bronchoscopy
Title
Frequency of dose adjustments
Description
From induction of sedation until recovery (eye opening/answer to verbal stimuli), in average 45 minutes
Time Frame
During bronchoscopy
Title
Cumulative propofol dose
Description
At time point when bronchoscope is removed (on average after 45 minutes)
Time Frame
At end of bronchoscopy
Title
Recovery time after bronchoscopy
Time Frame
During 2 hours after bronchoscopy

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects undergoing a planned, ambulatory flexible bronchoscopy (for transbronchial lung biopsy or endobronchial ultrasound guided procedures) in moderate sedation, aged between 18 and 85 years Exclusion Criteria: History of solid organ or bone marrow transplantation with the use of an immunosuppressive therapy HIV infection on anti-retroviral therapy Alcohol consumption more than two standard drinks per day Use of illicit drugs (heroin, opiates) Any contraindication to use propofol for sedation (e.g. allergy) Body mass index > 35 kg/m2 Mental disorder preventing appropriate judgment concerning study participation Missing written patient's informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel Franzen, MD
Organizational Affiliation
Division of Pulmonology
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Zurich
City
Zurich
ZIP/Postal Code
8091
Country
Switzerland

12. IPD Sharing Statement

Learn more about this trial

Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy

We'll reach out to this number within 24 hrs